361 related articles for article (PubMed ID: 20712426)
1. Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naïve Japanese patients with type 2 diabetes with or without metabolic syndrome.
Kutoh E
Endocr Res; 2010; 35(3):118-27. PubMed ID: 20712426
[TBL] [Abstract][Full Text] [Related]
2. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
3. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
5. Differential regulations of lipid profiles between Japanese responders and nonresponders treated with pioglitazone.
Kutoh E
Postgrad Med; 2011 Jan; 123(1):45-52. PubMed ID: 21293083
[TBL] [Abstract][Full Text] [Related]
6. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.
Mori Y; Itoh Y; Obata T; Tajima N
Endocrine; 2006 Feb; 29(1):143-8. PubMed ID: 16622303
[TBL] [Abstract][Full Text] [Related]
7. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
8. Insulin-dependent actions of pioglitazone in newly diagnosed, drug naïve patients with type 2 diabetes.
Kutoh E; Fukushima T
Endocrine; 2009 Jun; 35(3):333-40. PubMed ID: 19367381
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
[TBL] [Abstract][Full Text] [Related]
10. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
11. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
[TBL] [Abstract][Full Text] [Related]
12. Complementary effects on glycaemic and non-glycaemic parameters between responders and non-responders treated with pioglitazone and canagliflozin in drug-naive subjects with type 2 diabetes.
Kutoh E; Kuto AN; Wada A; Kurihara R; Kojima R
Int J Clin Pract; 2021 Dec; 75(12):e14914. PubMed ID: 34551185
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients.
Genovese S; Passaro A; Brunetti P; Comaschi M; Cucinotta D; ; Egan CG; Chinea B; Bravi F; Di Pietro C
J Endocrinol Invest; 2013 Sep; 36(8):606-16. PubMed ID: 23511244
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes.
Tan MH; Johns D; Glazer NB
Clin Chem; 2004 Jul; 50(7):1184-8. PubMed ID: 15117857
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome.
Kato T; Sawai Y; Kanayama H; Taguchi H; Terabayashi T; Taki F; Yamada K; Yamazaki Y; Hayakawa N; Suzuki A; Oda N; Katada N; Itoh M
Exp Clin Endocrinol Diabetes; 2009 Nov; 117(10):593-9. PubMed ID: 19924605
[TBL] [Abstract][Full Text] [Related]
17. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pioglitazone and metformin efficacy using homeostasis model assessment.
Nagasaka S; Aiso Y; Yoshizawa K; Ishibashi S
Diabet Med; 2004 Feb; 21(2):136-41. PubMed ID: 14984448
[TBL] [Abstract][Full Text] [Related]
19. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
Nicholls SJ; Tuzcu EM; Wolski K; Bayturan O; Lavoie A; Uno K; Kupfer S; Perez A; Nesto R; Nissen SE
J Am Coll Cardiol; 2011 Jan; 57(2):153-9. PubMed ID: 21211686
[TBL] [Abstract][Full Text] [Related]
20. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
